Amneal Pharmaceuticals, Inc. - News - Press Releases

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 22, 2016

Impax Launches Generic Version of Kadian® (morphine sulfate) Extended Release Capsules, USP CII

Dec 20, 2016

Impax Laboratories Announces Leadership Transition

Nov 28, 2016

Impax Announces Appointment of J. Kevin Buchi to Board of Directors

Nov 22, 2016

Impax to Present at the 28th Annual Piper Jaffray Healthcare Conference

Nov 16, 2016

Liberty Science Center Appoints New Managing And Advisory Trustees To Board

Nov 09, 2016

Impax Reports Third Quarter 2016 Financial Results

Oct 31, 2016

Media Alert: Experts Available Now And At American College of Allergy, Asthma and Immunology (ACAAI) Scientific Meeting

Oct 24, 2016

Amneal Biosciences Introduces Second Institutional Product

Oct 18, 2016

Amneal Launches First Vagifem® Generic

Oct 06, 2016

Amneal Biosciences Launches First Product

Oct 04, 2016

Amneal wins Company of the Year, Americas at the Global Generics & Biosimilars Awards 2016

Oct 04, 2016

Impax to Report Third Quarter 2016 Results on November 9, 2016

Sep 22, 2016

Impax Launches Generic Version of Metadate CD® (Methylphenidate Hydrochloride Extended-Release Capsules)

Sep 07, 2016

Impax to Present at the Morgan Stanley Global Healthcare Conference

Aug 30, 2016

Impax Provides Update on Epinephrine Injection, USP Auto-Injector

Aug 26, 2016

Impax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers

Aug 22, 2016

Richard A. Bierly Appointed to Impax Laboratories Board of Directors

Aug 09, 2016

Impax Reports Second Quarter 2016 Financial Results

Jul 21, 2016

Impax Names Douglas S. Boothe President of Generics Division

Jul 07, 2016

Impax to Report Second Quarter 2016 Results on August 9, 2016

Jun 29, 2016

New Generic Equivalent for Lutera® 28

Jun 21, 2016

Impax Signs Definitive Agreements to Acquire Generic Products

Jun 16, 2016

Amneal Pharmaceuticals Honored with Best Overall Generics Manufacturer Award by Healthcare Distribution Alliance

Jun 14, 2016

Amneal Pharmaceuticals Company GmbH and Iconovo AB Execute Development and License Agreement

Jun 02, 2016

Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

May 10, 2016

Impax Reports First Quarter 2016 Financial Results

May 04, 2016

Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

Apr 18, 2016

Impax to Report First Quarter 2016 Results on May 10, 2016

Apr 14, 2016

Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of Directors

Apr 13, 2016

Impax Announces Availability of EMVERM™ (mebendazole) Chewable Tablets, 100 mg

Mar 24, 2016

Amneal Announces the Launch of Diclofenac Sodium Topical Gel 1%

Mar 11, 2016

Impax to Present at the Barclays Global Healthcare Conference

Mar 01, 2016

Impax to Present at the 37th Annual Raymond James Institutional Investors Conference

Feb 22, 2016

Impax Reports Fourth Quarter and Full Year 2015 Financial Results

Feb 17, 2016

Impax Receives FDA Approval for Generic Version of Adderall XR® (mixed salts of a single-entity amphetamine product) Capsules, CII

Feb 10, 2016

Chirag and Chintu Patel featured in the OECD Observer

Feb 02, 2016

Impax Receives Tentative FDA Approval for Generic Version of Vytorin® (ezetimibe and simvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg

Jan 21, 2016

Impax to Report Fourth Quarter and Full Year 2015 Results on February 22, 2016

Jan 15, 2016

Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets, 100 mg

Jan 05, 2016

Amneal Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference

Jan 05, 2016

Impax to Present at the 34th Annual J.P. Morgan Healthcare Conference

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.86.0.1